✦ LIBER ✦

Post-market drug safety evidence sources: an analysis of FDA drug safety communications

✍ Scribed by Chieko Ishiguro; Marni Hall; George A. Neyarapally; Gerald Dal Pan

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Review of Recent FDA Drug Safety Commu

✍ Thomas Kubiszyn, Sarah S. Mire 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 262 KB

Analysis of the Factors Influencing the

✍ Ishiguro, Chieko; Hinomura, Yasushi; Uemura, Keiko; Matsuda, Tsutomu 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 564 KB

Post-Marketing Surveillance of Prescript

✍ Chen, Brian K.; Yang, Y. Tony 📂 Article 📅 2013 🏛 Taylor and Francis Group 🌐 English ⚖ 166 KB

FDA Issues Early Communication About Ong

✍ Leslie H. Lang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Analysis of drug safety in an intensive

✍ Challet, C.; Bezençon, A.; Bovy, M.; Farah, C.; Schaad, N. 📂 Article 📅 2014 🏛 Elsevier 🌐 French ⚖ 244 KB

The European Post-marketing Observationa

✍ Siegfried Kasper; Hans-Jürgen Möller; Anthony Hale 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 187 KB